Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026

  • receipt Report ID : 196456
  • calendar_today Published On: Mar, 2021
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation

Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Chemotherapy

Peptide-Receptor Radionuclide Therapy

Others

Market segment by Application, can be divided into

Hospitals

Clinics

Ambulatory Surgical Centers

Others

Market segment by players, this report covers

Novartis

Pfizer

Fresenius Kabi

Teva Pharmaceuticals

Sun Pharma

Hutchison China MediTech Limited

Exelixis, Inc.

Tarveda Therapeutics

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics

1.2 Classification of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics by Type

1.2.1 Overview: Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Type in 2020

1.2.3 Chemotherapy

1.2.4 Peptide-Receptor Radionuclide Therapy

1.2.5 Others

1.3 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market by Application

1.3.1 Overview: Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Ambulatory Surgical Centers

1.3.5 Others

1.4 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size & Forecast

1.5 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Forecast by Region

1.5.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region, (2016-2021)

1.5.3 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Prospect (2016-2026)

1.5.4 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Prospect (2016-2026)

1.5.5 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Prospect (2016-2026)

1.5.6 South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Prospect (2016-2026)

1.5.7 Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Drivers

1.6.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Restraints

1.6.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Trends Analysis

2 Company Profiles

2.1 Novartis

2.1.1 Novartis Details

2.1.2 Novartis Major Business

2.1.3 Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions

2.1.4 Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 Novartis Recent Developments and Future Plans

2.2 Pfizer

2.2.1 Pfizer Details

2.2.2 Pfizer Major Business

2.2.3 Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions

2.2.4 Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 Pfizer Recent Developments and Future Plans

2.3 Fresenius Kabi

2.3.1 Fresenius Kabi Details

2.3.2 Fresenius Kabi Major Business

2.3.3 Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions

2.3.4 Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 Fresenius Kabi Recent Developments and Future Plans

2.4 Teva Pharmaceuticals

2.4.1 Teva Pharmaceuticals Details

2.4.2 Teva Pharmaceuticals Major Business

2.4.3 Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions

2.4.4 Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 Teva Pharmaceuticals Recent Developments and Future Plans

2.5 Sun Pharma

2.5.1 Sun Pharma Details

2.5.2 Sun Pharma Major Business

2.5.3 Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions

2.5.4 Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 Sun Pharma Recent Developments and Future Plans

2.6 Hutchison China MediTech Limited

2.6.1 Hutchison China MediTech Limited Details

2.6.2 Hutchison China MediTech Limited Major Business

2.6.3 Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions

2.6.4 Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 Hutchison China MediTech Limited Recent Developments and Future Plans

2.7 Exelixis, Inc.

2.7.1 Exelixis, Inc. Details

2.7.2 Exelixis, Inc. Major Business

2.7.3 Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions

2.7.4 Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.7.5 Exelixis, Inc. Recent Developments and Future Plans

2.8 Tarveda Therapeutics

2.8.1 Tarveda Therapeutics Details

2.8.2 Tarveda Therapeutics Major Business

2.8.3 Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions

2.8.4 Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue, Gross Margin and Market Share (2019-2021)

2.8.5 Tarveda Therapeutics Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players Market Share

3.2.2 Top 10 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players Market Share

3.2.3 Market Competition Trend

3.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Market Share by Type (2016-2021)

4.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Application (2016-2021)

5.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

6.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Type (2016-2026)

6.2 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Application (2016-2026)

6.3 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country

6.3.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Country (2016-2026)

6.3.2 United States Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Forecast (2016-2026)

6.3.3 Canada Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Forecast (2016-2026)

6.3.4 Mexico Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

7.1 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Type (2016-2026)

7.2 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Application (2016-2026)

7.3 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country

7.3.1 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Country (2016-2026)

7.3.2 Germany Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Forecast (2016-2026)

7.3.3 France Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Forecast (2016-2026)

7.3.4 United Kingdom Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Forecast (2016-2026)

7.3.5 Russia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Forecast (2016-2026)

7.3.6 Italy Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Type (2016-2026)

8.2 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Application (2016-2026)

8.3 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region

8.3.1 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Region (2016-2026)

8.3.2 China Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Forecast (2016-2026)

8.3.3 Japan Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Forecast (2016-2026)

8.3.4 South Korea Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Forecast (2016-2026)

8.3.5 India Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Forecast (2016-2026)

8.3.6 Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Forecast (2016-2026)

8.3.7 Australia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

9.1 South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Type (2016-2026)

9.2 South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Application (2016-2026)

9.3 South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country

9.3.1 South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Country (2016-2026)

9.3.2 Brazil Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Forecast (2016-2026)

9.3.3 Argentina Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Type (2016-2026)

10.2 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Application (2016-2026)

10.3 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country

10.3.1 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Country (2016-2026)

10.3.2 Turkey Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Forecast (2016-2026)

10.3.3 Saudi Arabia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Forecast (2016-2026)

10.3.4 UAE Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million) by Region (2016-2021)

Table 5. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Region (2021-2026)

Table 6. Novartis Corporate Information, Head Office, and Major Competitors

Table 7. Novartis Major Business

Table 8. Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions

Table 9. Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. Pfizer Corporate Information, Head Office, and Major Competitors

Table 11. Pfizer Major Business

Table 12. Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions

Table 13. Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. Fresenius Kabi Corporate Information, Head Office, and Major Competitors

Table 15. Fresenius Kabi Major Business

Table 16. Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions

Table 17. Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. Teva Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 19. Teva Pharmaceuticals Major Business

Table 20. Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions

Table 21. Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. Sun Pharma Corporate Information, Head Office, and Major Competitors

Table 23. Sun Pharma Major Business

Table 24. Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions

Table 25. Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. Hutchison China MediTech Limited Corporate Information, Head Office, and Major Competitors

Table 27. Hutchison China MediTech Limited Major Business

Table 28. Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions

Table 29. Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. Exelixis, Inc. Corporate Information, Head Office, and Major Competitors

Table 31. Exelixis, Inc. Major Business

Table 32. Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions

Table 33. Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 34. Tarveda Therapeutics Corporate Information, Head Office, and Major Competitors

Table 35. Tarveda Therapeutics Major Business

Table 36. Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions

Table 37. Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 38. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million) by Players (2019-2021)

Table 39. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Share by Players (2019-2021)

Table 40. Breakdown of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)

Table 41. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players Head Office, Products and Services Provided

Table 42. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Mergers & Acquisitions in the Past Five Years

Table 43. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics New Entrants and Expansion Plans

Table 44. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million) by Type (2016-2021)

Table 45. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Share by Type (2016-2021)

Table 46. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Forecast by Type (2021-2026)

Table 47. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Application (2016-2021)

Table 48. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Forecast by Application (2021-2026)

Table 49. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Type (2016-2021) & (USD Million)

Table 50. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Type (2021-2026) & (USD Million)

Table 51. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Application (2016-2021) & (USD Million)

Table 52. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Application (2021-2026) & (USD Million)

Table 53. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Country (2016-2021) & (USD Million)

Table 54. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Country (2021-2026) & (USD Million)

Table 55. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Type (2016-2021) & (USD Million)

Table 56. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Type (2021-2026) & (USD Million)

Table 57. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Application (2016-2021) & (USD Million)

Table 58. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Application (2021-2026) & (USD Million)

Table 59. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Country (2016-2021) & (USD Million)

Table 60. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Country (2021-2026) & (USD Million)

Table 61. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Type (2016-2021) & (USD Million)

Table 62. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Type (2021-2026) & (USD Million)

Table 63. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Application (2016-2021) & (USD Million)

Table 64. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Application (2021-2026) & (USD Million)

Table 65. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Region (2016-2021) & (USD Million)

Table 66. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Region (2021-2026) & (USD Million)

Table 67. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Type (2016-2021) & (USD Million)

Table 68. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Type (2021-2026) & (USD Million)

Table 69. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Application (2016-2021) & (USD Million)

Table 70. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Application (2021-2026) & (USD Million)

Table 71. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Country (2016-2021) & (USD Million)

Table 72. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Country (2021-2026) & (USD Million)

Table 73. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Type (2016-2021) & (USD Million)

Table 74. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Type (2021-2026) & (USD Million)

Table 75. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Application (2016-2021) & (USD Million)

Table 76. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Application (2021-2026) & (USD Million)

Table 77. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Country (2016-2021) & (USD Million)

Table 78. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Country (2021-2026) & (USD Million)

List of Figures

Figure 1. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Picture

Figure 2. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Type in 2020

Figure 3. Chemotherapy

Figure 4. Peptide-Receptor Radionuclide Therapy

Figure 5. Others

Figure 6. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Application in 2020

Figure 7. Hospitals Picture

Figure 8. Clinics Picture

Figure 9. Ambulatory Surgical Centers Picture

Figure 10. Others Picture

Figure 11. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026

Figure 12. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Forecast (2016-2026) & (USD Million)

Figure 13. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Region (2016-2026)

Figure 14. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Region in 2020

Figure 15. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)

Figure 16. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)

Figure 17. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)

Figure 18. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)

Figure 19. Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)

Figure 20. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Drivers

Figure 21. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Restraints

Figure 22. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Trends

Figure 23. Novartis Recent Developments and Future Plans

Figure 24. Pfizer Recent Developments and Future Plans

Figure 25. Fresenius Kabi Recent Developments and Future Plans

Figure 26. Teva Pharmaceuticals Recent Developments and Future Plans

Figure 27. Sun Pharma Recent Developments and Future Plans

Figure 28. Hutchison China MediTech Limited Recent Developments and Future Plans

Figure 29. Exelixis, Inc. Recent Developments and Future Plans

Figure 30. Tarveda Therapeutics Recent Developments and Future Plans

Figure 31. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Share by Players in 2020

Figure 32. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 33. Global Top 3 Players Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share in 2020

Figure 34. Global Top 10 Players Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share in 2020

Figure 35. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 36. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Share by Type in 2020

Figure 37. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share Forecast by Type (2021-2026)

Figure 38. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Share by Application in 2020

Figure 39. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share Forecast by Application (2021-2026)

Figure 40. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Sales Market Share by Type (2016-2026)

Figure 41. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Sales Market Share by Application (2016-2026)

Figure 42. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Country (2016-2026)

Figure 43. United States Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 44. Canada Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 45. Mexico Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 46. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Sales Market Share by Type (2016-2026)

Figure 47. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Sales Market Share by Application (2016-2026)

Figure 48. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Country (2016-2026)

Figure 49. Germany Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 50. France Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 51. United Kingdom Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 52. Russia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 53. Italy Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 54. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Sales Market Share by Type (2016-2026)

Figure 55. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Sales Market Share by Application (2016-2026)

Figure 56. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Region (2016-2026)

Figure 57. China Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 58. Japan Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 59. South Korea Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 60. India Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 61. Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 62. Australia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 63. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Sales Market Share by Type (2016-2026)

Figure 64. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Sales Market Share by Application (2016-2026)

Figure 65. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Country (2016-2026)

Figure 66. Brazil Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 67. Argentina Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 68. Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Sales Market Share by Type (2016-2026)

Figure 69. Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Sales Market Share by Application (2016-2026)

Figure 70. Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Country (2016-2026)

Figure 71. Turkey Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 72. Saudi Arabia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 73. UAE Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 74. Methodology

Figure 75. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz